Mary Scafidis
Senior Vice President, Investor Relations and Communications
Replay available
AptarGroup, Inc. (NYSE: ATR) Q1 2025 earnings conference call, held 2025-05-02. Replay captured from the company's public earnings webcast.

Senior Vice President, Investor Relations and Communications
President and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Analyst, Bank of America
Analyst
Analyst, Raymond James
Analyst, Jefferies
Analyst, William Blair
Analyst, Wells Fargo
Ladies and gentlemen, thank you for standing by. Welcome to APTA's 2025 First Quarter Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Introducing today's conference call is Mrs. Mary Scafidis, Senior Vice President, Investor Relations and Communications. Please go ahead. Thank you. Hello, everyone, and thanks for being with us today. Our speakers for the call are Stefan Tanda, our President and CEO, and Vanessa Canu, our Executive Vice President and CFO. A press release and accompanying slide deck have been posted on our website under the Investor Relations page. During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for reconciliations of non-GAAP measures to the most comparable GAAP measures discussed during this earnings call. As always, we will also post a replay of this call on our website. I would now like to turn the call over to Stefan. Stefan, over to you. Thank you, Mary, and good morning, everyone. We appreciate you joining us on the call today. I will begin my remarks by highlighting our first quarter results. Later in the call, Vanessa Canu, our CFO, will provide additional details on key drivers for the quarter. Starting on slide three, for the first quarter, we delivered adjusted earnings per share of $1.20. Neutralizing for currency effects and tax, earnings per share would have increased approximately 5% over the prior year period. We saw solid demand for our pharma segment's proprietary drug delivery systems, especially technologies for emerg...